Registry of Hypogonadism in Men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men

References

• Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123–35
   PubMed Web of Science ®Google Scholar
• Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241–7
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005;63:381–94
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005;63:280–93
   PubMed Web of Science ®Google Scholar
• Liverman CT, Blazer DG, editors. Testosterone and aging: clinical research directions. Washington, DC: The National Academies Press; 2004
   Google Scholar
• Minnemann T, Schubert M, Hubler D, et al. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Aging Male 2007;10:155–8
   PubMed Web of Science ®Google Scholar
• Cunningham GR, Toma SM. Clinical review: why is androgen replacement in males controversial? J Clin Endocrinol Metab 2011;96:38–52
   PubMedGoogle Scholar
• Swerdloff R, Wang C. Testosterone treatment of older men–why are controversies created? J Clin Endocrinol Metab 2011;96:62–5
   PubMedGoogle Scholar
• Morgentaler A, Bruning CO, 3rd DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904–6
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310–20
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–59
   PubMed Web of Science ®Google Scholar
• Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451–7
   PubMed Web of Science ®Google Scholar
• Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560–75
   PubMed Web of Science ®Google Scholar
• Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:29–39
   PubMed Web of Science ®Google Scholar
• Khera M, Bhattacharyam RK, Blick G, et al. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the US (TriUS). J Sex Med 2011;8:3204–13
   PubMedGoogle Scholar
• Miner MM, Khera M, Bhattacharya RK, et al. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med 2011;123:17–27
   PubMed Web of Science ®Google Scholar
• Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: A user’s guide. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA29020050035I TO1.) AHRQ Publication No. 07-EHC001-1. Rockville (MD): Agency for Healthcare Research and Quality. April 2007; 2007
   Google Scholar
• Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5–12
   PubMed Web of Science ®Google Scholar
• Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–30
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57; discussion 1564
   PubMed Web of Science ®Google Scholar
• Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C. A new ‘Aging Male’s Symptoms’ (AMS) rating scale. Aging Male 1999;2:105–14
   Google Scholar
• Heinemann LA, Thiel C, Assmann A, et al. Sex differences in ‘climacteric symptoms’ with increasing age? A hypothesis-generating analysis of cross-sectional population surveys. Aging Male 2000;3:124–31
   PubMedGoogle Scholar
• D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180–7
   PubMed Web of Science ®Google Scholar
• Leaverton PE, Sorlie PD, Kleinman JC, et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis 1987;40:775–84
   PubMedGoogle Scholar
• Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24
   PubMed Web of Science ®Google Scholar
• Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007;99:1395–400
   PubMedGoogle Scholar
• Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005;65:549–53
   Google Scholar
• Roobol MJ, Zappa M, Maattanen L, Ciatto S. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007;67:439–46
   Google Scholar
• Zitzmann M, Mattern A, Hanisch J, et al. IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1438 men. J Sex Med 2012. [Epub ahead of print]. PMID:22812645
   Google Scholar
• Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050–8
   PubMed Web of Science ®Google Scholar
• Schroeder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003;92:1–13
   Google Scholar